All Stories

  1. Everolimus-eluting stent platforms in percutaneous coronary intervention: comparative effectiveness and outcomes
  2. Two-Year Follow-Up OCT Images of 2 Bifurcation Lesions Treated With Bioresorbable Vascular Scaffolds
  3. A 2-year follow-up of a randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels the BELLO study
  4. The role of TNF-α, Fas/Fas ligand system and NT-proBNP in the early detection of asymptomatic left ventricular dysfunction in cancer patients treated with anthracyclines
  5. Procedural Feasibility and Clinical Outcomes in Propensity-Matched Patients Treated With Bioresorbable Scaffolds vs New-Generation Drug-Eluting Stents
  6. Transcatheter aortic valve implantation with a Direct Flow Medical valve in a patient with severe aortic regurgitation due to degenerated aortic stentless bioprosthesis
  7. Bioresorbable scaffolds for the treatment of complex lesions: are we there yet?
  8. Acute heart failure management in a young patient requiring complex left main percutaneous coronary intervention, Impella 2.5 and transcatheter aortic valve implantation
  9. Comparison of 2-year outcomes between zotarolimus-eluting and everolimus-eluting new-generation cobalt-chromium alloy stents in real-world diabetic patients
  10. Association Between Corrected QT Interval and Inflammatory Cytokines in Rheumatoid Arthritis
  11. Diagnostic Coronary Angiography Is Getting Old!∗
  12. Hybrid Coronary Revascularization
  13. Side Branch Occlusion After Bioresorbable Vascular Scaffold Implantation
  14. In-Scaffold Restenosis in a Previous Left Main Bifurcation Lesion Treated With Bioresorbable Scaffold V-Stenting
  15. Short-term outcomes following “full-plastic jacket” everolimus-eluting bioresorbable scaffold implantation
  16. Early detection of subclinical left ventricular myocardial dysfunction in patients with chronic kidney disease
  17. Relationship between dimethylarginine dimethylaminohydrolase gene variants and asymmetric dimethylarginine in patients with rheumatoid arthritis
  18. Optimal Duration of Dual Antiplatelet Therapy After Implantation of Bioresorbable Vascular Scaffolds: Lessons From Optical Coherence Tomography
  19. One-Year Follow-Up Optical Coherence Tomography After Implantation of Bioresorbable Vascular Scaffolds for a Chronic Coronary Total Occlusion
  20. Why Do We Need Post-Dilation After Implantation of a Bioresorbable Vascular Scaffold Even for a Soft Lesion?
  21. TCT-776 Risk Factors And Clinical Significance Of Intra-Procedural Haemodynamic Instability In Patients Undergoing Transcatheter Aortic Valve Implantation
  22. TCT-705 Trascatheter Aortic Valve Implantation Outcomes With Self-Expandable and Balloon-Expandable Devices in Patients with Mixed Aortic Valve Stenosis
  23. TCT-612 Clinical outcomes in patients with calcified lesions, treated with bioresorbable vascular scaffolds
  24. TCT-771 Comparison of post TAVR paravalvular regurgitation between Edwards SAPIEN 3 and Edwards SAPIEN XT; early, single center experience
  25. TCT-627 Comparison of Procedural Feasibility Between Bioresorbable Vascular Scaffold and New-generation Drug Eluting Stent in an All-comer Population
  26. TCT-250 A Comparison of Cobalt-Chromium Alloy Stents: Zotarolimus-eluting and Everolimus-eluting in Patients with Diabetes
  27. TCT-244 Real World 1-year Clinical Outcomes of Bioresorbable Vascular Scaffold Implanted in Diabetic Patients
  28. TCT-630 Impact of Calcified Plaque on Stent Strut Distribution of Bioresorbable Vascular Scaffolds Versus Metallic Everolimus-eluting Stents: An Optical Coherence Tomography Analysis
  29. TCT-631 Clinical Outcome of Patients With Complex Lesion Treated With Bioresorbable Vascular Scaffold; Single Center Experience
  30. TCT-277 Synergy of Drug Coated Balloons plus Second-generation Drug Eluting Stents versus Second-generation Drug Eluting Stents: A Propensity Matched Analysis
  31. TCT-284 Synergy of Drug Coated Balloons plus Second-generation Drug Eluting Stents in lesions with high risk for restenosis
  32. TCT-229 First generation versus new generation drug-eluting stents for the treatment of ostial/midshaft lesions in unprotected left main coronary artery: The Milan and New-Tokyo (MITO) registry
  33. TCT-743 To Predilate or To Not Predilate In Transcatheter Aortic Valve Implantation? Single-Center Experience With Self-Expandable CoreValve Revalving System
  34. TCT-296 Routine Screening Of Coronary Artery Disease With Computed Tomography Coronary Angiography In Place Of Invasive Coronary Angiography In Patients Undergoing Transcatheter Aortic Valve Implantation
  35. TCT-187 Procedural Feasibility and Clinical Efficacy of Bioresorbable Vascular Scaffold in the Treatment of Bifurcation Lesions: Results from a Single Center Experience
  36. TCT-609 Comparison of one year outcomes in real world patients treated with a polymer free amphilimus eluting coronary stent versus second generation everolimus eluting stents
  37. TCT-694 Early Outcomes With Direct Flow Medical Versus 1°-Generation Transcatheter Aortic Valve Devices: A Single-Center Propensity-Matched Analysis
  38. First generation versus new generation drug-eluting stents for the treatment of ostial/midshaft lesions in unprotected left main coronary artery: The Milan and New-Tokyo (MITO) registry
  39. The South Asian Genome
  40. Delayed Disruption of a Bioresorbable Vascular Scaffold
  41. A Case of True Left Main Bifurcation Treated With Bioresorbable Everolimus-Eluting Stent V-Stenting
  42. Tardive Coronary Obstruction By a Native Leaflet After Transcatheter Aortic Valve Replacement in a Patient With Heavily Calcified Aortic Valve Stenosis
  43. Unanticipated Pseudocoarctation Highlights the Importance of Visualizing Aortic Arch Anatomy Before Transfemoral Transcatheter Aortic Valve Implantation
  44. Bioresorbable vascular scaffolds for left main lesions; a novel strategy to overcome limitations
  45. Strategy for optimal side-branch positioning of bioresorbable vascular scaffolds in dedicated 2-stent techniques: Insights from optical coherence tomography
  46. Bioresorbable vascular scaffold strut disruption after crossing with an optical coherence tomography imaging catheter
  47. Acute stent thrombosis of a bioresorbable vascular scaffold implanted for ST-segment elevation myocardial infarction
  48. A case of Kawasaki’s disease with extensive calcifications needing rotational atherectomy with a 2.5mm burr
  49. 111 Investigation of the Validity of Cardiovascular Death Certification Amongst Uk Indian Asians and Europeans
  50. Conventional surgery and transcatheter closure via surgical transapical approach for paravalvular leak repair in high-risk patients: results from a single-centre experience
  51. Outcomes in coronary stent trials—1 year is not enough
  52. After 3 Decades, at Long Last, a New Device to Deal With Calcific Lesions∗
  53. Prevalence of Electrocardiographic Anomalies in Young Individuals
  54. Hybrid percutaneous coronary revascularisation for a patient with left main bifurcation and extensive, diffuse coronary artery disease
  55. Early results following everolimus-eluting bioresorbable vascular scaffold implantation for the treatment of in-stent restenosis
  56. Is “the bigger the better” still valid for drug-eluting stents?
  57. No more metallic cages: An attractive hybrid strategy with bioresorbable vascular scaffold and drug-eluting balloon for diffuse or tandem lesions in the same vessel
  58. First case reported of transcatheter aortic valve implantation in a patient affected by Fabry’s Disease and severe low-flow low-gradient aortic valve stenosis
  59. The role of intravascular ultrasound and quantitative angiography in the functional assessment of intermediate coronary lesions: Correlation with fractional flow reserve
  60. Coronary heart disease in Indian Asians
  61. Poster session Thursday 12 December - PM: 12/12/2013, 14:00-18:00 * Location: Poster area
  62. Poster Session Saturday 14 December - AM: 14/12/2013, 08:30-12:30 * Location: Poster area
  63. Prolonged QTc interval predicts all-cause mortality in patients with rheumatoid arthritis: an association driven by high inflammatory burden
  64. Derangement of hemostasis in rheumatoid arthritis: association with demographic, inflammatory and metabolic factors
  65. Iatrogenic communications between aortic root and right ventricle/left atrium after transcatheter aortic valve replacement
  66. Physiological Right Ventricular Adaptation in Elite Athletes of African and Afro-Caribbean Origin
  68. Increased left ventricular trabeculation in highly trained athletes: do we need more stringent criteria for the diagnosis of left ventricular non-compaction in athletes?
  69. Cardiac adaptation to exercise in adolescent athletes of African ethnicity: an emergent elite athletic population
  70. Poster Session: Right ventricular systolic function
  71. Tuesday, 28 August 2012
  72. Investigating novel regulators and inhibitors of aortic valve calcification
  73. Pocket-size hand-held cardiac ultrasound as an adjunct to clinical examination in the hands of medical students and junior doctors
  74. 102 Pocket-size hand-held cardiac ultrasound in the hands of students and junior doctors: does it improve diagnostic accuracy over history, physical examination and ECG?
  75. 061 QT prolongation associates with increased mortality in patients with rheumatoid arthritis
  76. 074 The prevalence and significance of left ventricular hypertrabeculation in highly trained athletes
  77. Lack of association between polymorphisms of thrombogenic genes and disease susceptibility in rheumatoid arthritis
  78. Anti-tumour necrosis factor alpha therapy improves insulin sensitivity in normal-weight but not in obese patients with rheumatoid arthritis
  79. Apolipoprotein E Gene Polymorphisms Are Strong Predictors of Inflammation and Dyslipidemia in Rheumatoid Arthritis
  80. Poster Session 4: Friday 9 December 2011, 14:00-18:00 * Location: Poster Area
  81. 49 Ethnic variation in QT interval among highly trained athletes
  82. 60 Ethnic differences in repolarisation patterns and left ventricular remodelling in highly trained male adolescent (14-18 years) athletes
  83. The prevalence, distribution, and clinical outcomes of electrocardiographic repolarization patterns in male athletes of African/Afro-Caribbean origin
  84. Anti-TNFα therapy may lead to blood pressure reductions through improved endothelium-dependent microvascular function in patients with rheumatoid arthritis
  85. Rheumatoid arthritis susceptibility genes associate with lipid levels in patients with rheumatoid arthritis
  86. Disease activity and low physical activity associate with number of hospital admissions and length of hospitalisation in patients with rheumatoid arthritis
  87. Subclinical peripheral arterial disease in rheumatoid arthritis
  88. The relationship of systemic right ventricular function to ECG parameters and NT-proBNP levels in adults with transposition of the great arteries late after Senning or Mustard surgery
  89. Are Lipid Ratios Less Susceptible to Change With Systemic Inflammation Than Individual Lipid Components in Patients With Rheumatoid Arthritis?
  90. Microalbuminuria in rheumatoid arthritis in the post penicillamine/gold era: association with hypertension, but not therapy or inflammation
  91. Genetics [315-318]: 315. Investigation of Association of the Erap1 Gene with Psoriatic Arthritis
  92. Rheumatoid Arthritis: Clinical Aspects [322-355]: 322. The Effect of Biologics on Cardiovascular Disease in Patients with Rheumatoid Arthritis: A Systematic Literature Review
  93. Cytokines and Inflammatory Mediators [30-39]: 30. The LPS Stimulated Production of Interleukin-10 is not Associated with -819C/T and -592C/A Promoter Polymorphisms in Healthy Indian Subjects
  94. Target organ damage in patients with rheumatoid arthritis: The role of blood pressure and heart rate
  95. What predicts obesity in patients with rheumatoid arthritis? An investigation of the interactions between lifestyle and inflammation
  96. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk?
  97. Development and initial validation of a heart disease knowledge questionnaire for people with rheumatoid arthritis
  98. The magnitude of sudden cardiac death in the young: a death certificate-based review in England and Wales
  99. Prevalence of risk factors for statin-induced myopathy in rheumatoid arthritis patients
  100. Atherosclerosis in Rheumatoid Arthritis Versus Diabetes: A Comparative Study
  101. Statin therapy after first stroke reduces 10-year stroke recurrence and improves survival
  102. Association of interleukin-6 (IL-6)-174G/C gene polymorphism with cardiovascular disease in patients with rheumatoid arthritis: The role of obesity and smoking
  103. Association of physical inactivity with increased cardiovascular risk in patients with rheumatoid arthritis
  104. Cardiovascular risk factors and not disease activity, severity or therapy associate with renal dysfunction in patients with rheumatoid arthritis: Table 1
  105. Heart Disease Fact Questionnaire—Rheumatoid Arthritis
  106. Association of the TRAF1/C5 locus with increased mortality, particularly from malignancy or sepsis, in patients with rheumatoid arthritis
  107. Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60- more than just an anti-inflammatory effect? A cross sectional study
  108. Uric acid is a strong independent predictor of renal dysfunction in patients with rheumatoid arthritis
  109. Use of methotrexate therapy is not associated with decreased prevalence of metabolic syndrome - authors' response
  110. Galectin-2(LGALS2)3279C/T Polymorphism may be Independently Associated with Diastolic Blood Pressure in Patients with Rheumatoid Arthritis
  111. Lack of an Association of GNB3 C825T Polymorphism and Blood Pressure in Patients with Rheumatoid Arthritis
  112. Underweight and obese states both associate with worse disease activity and physical function in patients with established rheumatoid arthritis
  113. Transforming growth factor- 1 869T/C, but not interleukin-6 -174G/C, polymorphism associates with hypertension in rheumatoid arthritis
  114. “Cardiovascular” Drugs in Rheumatoid Arthritis: Killing Two Birds with One Stone?
  115. Associations of obesity with modifiable risk factors for the development of cardiovascular disease in patients with rheumatoid arthritis
  116. The inter-operator variability in measuring waist circumference and its potential impact on the diagnosis of the metabolic syndrome
  117. Metabolism in Patients with Rheumatoid Arthritis: Resting Energy Expenditure, Physical Activity and Diet-Induced Thermogenesis. Invited Review
  118. Hypertension in rheumatoid arthritis
  119. Six-step management of hypertension in patients with rheumatoid arthritis
  120. Lymphotoxin 252A>G polymorphism is common and associates with myocardial infarction in patients with rheumatoid arthritis
  121. Cigarette smoking associates with body weight and muscle mass of patients with rheumatoid arthritis: a cross-sectional, observational study
  122. Polymorphisms of the Endothelin-1 Gene Associate with Hypertension in Patients with Rheumatoid Arthritis
  123. Lack of association between glucocorticoid use and presence of the metabolic syndrome in patients with rheumatoid arthritis: a cross sectional study
  124. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis
  125. New resting energy expenditure prediction equations for patients with rheumatoid arthritis
  126. Rheumatoid arthritis, cardiovascular disease and physical exercise: a systematic review
  127. Serum uric acid is independently associated with hypertension in patients with rheumatoid arthritis
  128. Blockade of tumour necrosis factor-  in rheumatoid arthritis: effects on components of rheumatoid cachexia
  129. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis
  130. Association of serum uric acid with cardiovascular disease in rheumatoid arthritis
  131. Polypharmacy among people with rheumatoid arthritis: the role of age, disease duration and comorbidity
  132. B-cell differentiation immunophenotypes in classical Hodgkin lymphomas